TSBX Stock Overview
A clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Turnstone Biologics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.61 |
| 52 Week High | US$13.20 |
| 52 Week Low | US$1.63 |
| Beta | 0 |
| 1 Month Change | -4.04% |
| 3 Month Change | -37.86% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.27% |
Recent News & Updates
Shareholder Returns
| TSBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | -0.4% | -0.6% |
| 1Y | n/a | 5.5% | 22.2% |
Return vs Industry: Insufficient data to determine how TSBX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TSBX performed against the US Market.
Price Volatility
| TSBX volatility | |
|---|---|
| TSBX Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TSBX's share price has been volatile over the past 3 months.
Volatility Over Time: TSBX's weekly volatility has decreased from 26% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 82 | Sammy Farah | turnstonebio.com |
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company’s lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors.
Turnstone Biologics Corp. Fundamentals Summary
| TSBX fundamental statistics | |
|---|---|
| Market cap | US$60.37m |
| Earnings (TTM) | -US$74.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs TSBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$61.12m |
| Gross Profit | -US$61.12m |
| Other Expenses | US$13.75m |
| Earnings | -US$74.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TSBX perform over the long term?
See historical performance and comparison